OMCL News & Events

Omnicell announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Njoku will retain his role of Chief Operating Officer, COO, while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnicell's solution portfolio.

The FDA is aware that Omnicell has issued a letter to affected customers recommending certain syringe labels used with the i.v.STATION automated compounding system be removed from where they are used or sold. Affected devices: IVSTATION SYRINGE sterile label (40MMX40MM) - part number 258920028; IVSTATION SYRINGE sterile label (20MMX40MM) - part number 258920029. On April 10, Omnicell sent all affected customers a letter recommending the following actions: Do not use labels affected by this recall. If you or your staff locate any affected labels, immediately segregate and contact Omnicell Technical Support. Omnicell received a report of mislabeling that could affect sterile syringe labels produced using i.v.STATION. Omnicell identified inconsistent label detection behavior across i.v.STATION printers when using the sterile labels affected by this recall. Inconsistent label detection could result in unlabeled or mislabeled syringe preparations after compounding completion where the above identified sterile labels are utilized. As of April 10, Omnicell has reported no serious injuries or deaths associated with this issue.